Publication:
Sertraline Hepatotoxicity: Report of a Case and Review of the Literature

dc.contributor.authorGÜNDÜZ, FEYZA
dc.contributor.authorsTabak, Fehmi; Gunduz, Feyza; Tahan, Veysel; Tabak, Omur; Ozaras, Resat
dc.date.accessioned2022-03-10T15:25:04Z
dc.date.accessioned2026-01-10T19:58:24Z
dc.date.available2022-03-10T15:25:04Z
dc.date.issued2009
dc.description.abstractSertraline is a commonly prescribed selective serotonin reuptake inhibitor drug. Hepatotoxicity caused by sertraline is rare. Asymptomatic elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels have been rarely reported and shortly normalize after discontinuation of the agent. We present a case of severe drug-induced hepatitis in a patient receiving sertraline. To our knowledge, this is the seventh case in the medical literature as being associated with severe hepatotoxicity. Since it is extremely rare, we do not suggest a strict laboratory monitoring. However, sertraline should be discontinued in cases with symptoms implying hepatotoxicity and the patients should be informed of the potential of this side effect.
dc.identifier.doi10.1007/s10620-008-0524-3
dc.identifier.eissn1573-2568
dc.identifier.issn0163-2116
dc.identifier.pubmed18958618
dc.identifier.urihttps://hdl.handle.net/11424/220093
dc.identifier.wosWOS:000266654900031
dc.language.isoeng
dc.publisherSPRINGER
dc.relation.ispartofDIGESTIVE DISEASES AND SCIENCES
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectSertraline
dc.subjectHepatotoxicity
dc.subjectTransaminase
dc.titleSertraline Hepatotoxicity: Report of a Case and Review of the Literature
dc.typereview
dspace.entity.typePublication
oaire.citation.endPage1591
oaire.citation.issue7
oaire.citation.startPage1589
oaire.citation.titleDIGESTIVE DISEASES AND SCIENCES
oaire.citation.volume54

Files